Resverlogix Corp.

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. The company's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. Resverlogix can be followed on its blog at http://www.resverlogix.com/blog and via Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX

Expert Comments:

"Resverlogix Corp. is finally moving into a pivotal clinical trial with its epigenetic inhibitor RVX-208 (apabetalone), developed to increase levels of apolipoprotein A1 (ApoA1), a component of high-density lipoprotein (HDL), the "good" cholesterol. . .this trial will contain more than 2,400 high-risk cardiovascular patients with coronary artery disease and type 2 diabetes. The primary endpoint will be time to first occurrence of a major adverse cardiovascular event (MACE), which could be a non-fatal myocardial infarction, stroke or death. RVX-208 inhibits the bromodomain extraterminal domain (BET), and so they are calling the trial BETonMACE. . .Resverlogix had some interesting results with RVX-208 in its smaller proof-of-concept trials. In a couple of its more recent studies, it has gotten equivocal results. The company needs this defining trial. Results should be available in Q2/18, which sounds like a long time, but it's not when you're talking about a cardiovascular outcomes trial. . .Resverlogix has had a powerful run-up, but keep in mind that its U.S. dollar valuation is still only ~$162M. If RVX-208 is successful, there is a lot of upside left. . .you have to give kudos to the management team for committing to a large clinical outcomes trial." read more >

Nisha Hirani, Zacks Small-Cap Research (1/19/16)
"At the current price, we view Resverlogix Corp. shares as undervalued and as providing long-term upside potential. We have raised our price target to $4/share, and we continue to rate the stock a Buy. We believe that the orphan disease program, as well as further exploration by the company into areas such as renal disease, could provide further upside to our valuation in the near future."

Bjarke Krysel Christensen, Seeking Alpha (12/29/15)
"Resverlogix Corp.'s clinical trials data were excellent (yet not prospectively defined), and the exercise—while waiting for a confirmation of the results from the phase 3 trial—is therefore to look into the science to make the best possible guess on whether the results were pure happenstance or if they were the result of the drug, RVX-208. While the scientific literature is very complex and often contradicting, it appears to be possible to piece together a rather coherent picture of RVX-208 as a drug with a promising profile in diabetic heart disease."

Management Q&A: View From the Top
Donald McCaffrey
The evidence is mounting: Resverlogix Corp.'s first-in-class, epigenetics-based drug candidate has demonstrated its ability to significantly reduce major adverse cardiac events in three consecutive clinical trials. That, company President and CEO Donald McCaffrey tells The Life Sciences Report, is why RVX-208 will likely be a blockbuster.
read more >
Dan Trang, Stonegate Capital Partners (8/17/15)
"Resverlogix Corp. attained Phase 3 status for its BETonMACE trial and is set to begin in fall 2015. . .the trial will be held at over 40 European and possible U.S. sites with a 1,500–2,500 patient minimum, and its primary endpoint is to show major adverse cardiac events reduction of 20%."

"Resverlogix Corp. is a name I think investors should put on the radar. The company will enroll the first patient in its all-important BETonMACE Phase 3 clinical trial with RVX-208 in the Q4/15. RVX-208 is a first-in-class selective bromodomain and extra-terminal domain (BET) antagonist designed to reduce the incidence of major adverse cardiac events (MACE) in high-risk patients with diabetes mellitus and low HDL cholesterol. Previous data with RVX-208 showed the drug reduced incidents of MACE in this high-risk population, as well as conferred a benefit to patients with chronic kidney disease and elevated c-reative protein. We are intrigued by Resverlogix because of the targeted nature of RVX-208, based on all the company has learned from previous Phase 2 clinical studies. Resverlogix is now well capitalized, and since it is going after an area where big pharma has clearly shown an interest, we think that if results from the BETonMACE Phase 3 program are positive, the stock could have a significant revaluation to much higher levels." read more >

"Resverlogix Corp. is active in targeting cardiovascular disease. It has a proprietary drug development platform that's based on targeting bromodomain and extra terminal (BET) domain proteins. BET proteins have potential in many diseases, including cardiovascular disease, neurodegenerative disease and diabetes. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. . .using epigenetics (to target cardiovascular disease) is getting more emphasis from scientists and cardio specialists. The approach being developed by Resverlogix is a small molecule that can uncover the involved environmental and individual aspects of lifestyle that directly interact with the genome to influence epigenetic change in the DNA of a person. The company is targeting patients who have diabetes mellitus or chronic kidney failure who are at high risk for cardiovascular disease. . .the company may have the answer to developing a new generation of cardio drugs. . ." read more >

More Expert Comments

Experts Following This Company

Alan Leong, CEO – BioWatch News
Jason Napodano, Managing Director and Senior Biotech Analyst
Dan Trang – Stonegate Securities
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
Phase 3 Status from European Regulatory Authority for BETonMACE Clinical Trial
Combination Licensing and Equity Arrangement with China-Based Shenzhen Hepalink Pharmaceutical Co., Ltd.
Two Patents for RVX-208 in China